		Company Profile
		Mangement Team
		Board of Directors
		Scientific Advisory Board
		Investigators & Consultants

Clinical Investigators

Professor Donald Lamm, MD, FACS

During his urology residency, Prof. Lamm, primary investigator for BioCancell's Phase IIb bladder cancer clinical trial, developed an animal model for bladder cancer and found that the TB vaccine, BCG, inhibited tumor growth. After residency he began his academic career as Assistant Professor of Surgery at the University of Texas Health Sciences Center, rising in rank to Professor and Acting Chairman of the Division of Urology. His VA and NIH research resulted in clinical studies that led to the FDA approval of BCG for bladder cancer. He was recently recruited to the Mayo Clinic, Scottsdale, as Vice Chair for Research in the Department of Urology. Prof. Lamm's work is in part responsible for bladder cancer being one of only 5 cancers in the United States that has seen a reduced mortality despite an increased incidence.

Over 28 years in academic practice, he authored over 270 peer-reviewed medical and scientific articles, and in addition to new treatments of bladder cancer he has developed new approaches to the treatment of renal and prostate cancer as well.

Professor Abraham Ami Sidi, MD

Prof. Sidi is a principal investigator for BioCancell's Phase IIb bladder cancer clinical trial. He is Associate Professor of Surgery and Urology, Tel Aviv University, Sackler Faculty of Medicine and Chairman, Department of Urologic Surgery, Edith Wolfson Medical Center, Holon, Israel, where the trial is taking place.

Professor Abraham Czerniak, MD
Prof. Czerniak is a principal investigator for BioCancell's Phase IIb bladder cancer clinical trial. He is Associate Clinical Professor at Tel Aviv University, Sackler Faculty of Medicine, and the Director of the Department of General Surgery and Hepatobiliary surgery at the Sheba Medical Center, Tel Hashomer, Israel.

Prof. Czerniak is a recognized specialist in oncological surgery and particularly in hepatobiliary and pancreatic surgery.

Consultants

Regulatory Affairs Consultant: Dr. Janet Ransom

Dr. Ransom has over 20 years experience in biomedical research including product inception, research, development, clinical trials, and product licensure. She has managed diverse projects including the development of therapeutic cancer vaccines, therapeutic biological products and drugs to treat carcinomas, genetically engineered T cells for the treatment of AIDS/HIV, antitoxins for the treatment of neurotoxins, biological defense vaccines, medications for the treatment of substance abuse, and cardiovascular disease in vitro diagnostic tests. She has been involved with the regulatory development strategy, clinical trial design, pre-clinical development plans, and data analysis and reporting to support product licensure. She has designed and written Phase 1, 2, 3, and 4 clinical protocols to assess the safety and therapeutic effect of numerous biological and chemical agents for the treatment of malignancies. Furthermore, she has analyzed data from multi-institutional clinical trials and written the Clinical Summary Reports of numerous phase 2 and 3 studies according to the ICH Guidelines for inclusion in Biologics License Applications and New Drug Applications. She established systems specifications and implemented system installation, validation, release for production, and system oversight for multiple large multicenter clinical trials enrolling thousands of study participants.